This site is intended for healthcare professionals
News

Omeros Corporation submits its BLA to the FDA for narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Read time: 1 mins
Last updated:19th Nov 2020
Published:19th Nov 2020
Condition: Thrombotic Microangiopathies /HSCT- TMA
Type: drug
Register free for full access to medthority.com